PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia

High metabolic flexibility is pivotal for the persistence and therapy resistance of acute myeloid leukemia (AML). In 20–30% of AML patients, activating mutations of FLT3, specifically FLT3-ITD, are key therapeutic targets. Here, we investigated the influence of FLT3-ITD on AML metabolism. Nuclear Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshamleh, Islam, Kurrle, Nina, Makowka, Philipp, Bhayadia, Raj, Kumar, Rahul, Süsser, Sebastian, Seibert, Marcel, Ludig, Damian, Wolf, Sebastian, Koschade, Sebastian E., Stoschek, Karoline, Kreitz, Johanna, Fuhrmann, Dominik C., Toenges, Rosa, Notaro, Marco, Comoglio, Federico, Schuringa, Jan Jacob, Berg, Tobias, Brüne, Bernhard, Krause, Daniela S., Klusmann, Jan-Henning, Oellerich, Thomas, Schnütgen, Frank, Schwalbe, Harald, Serve, Hubert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681906/
https://www.ncbi.nlm.nih.gov/pubmed/37935978
http://dx.doi.org/10.1038/s41375-023-02041-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681906/
https://www.ncbi.nlm.nih.gov/pubmed/37935978
http://dx.doi.org/10.1038/s41375-023-02041-5

Ejemplares similares